Oppenheimer positive on Gilead's HIV pipeline, despite FDA approval of Tivicay yesterday

Gilead Sciences (GILD +0.4%) gets a boost from positive comments out of Oppenheimer this morning.

The firm notes the FDA approved GSK's Tivicay, a competitor to GILD's HIV medicines, yesterday.

The approval doesn't come as a surprise, and although they consider it to be a meaningful competitor to GILD's HIV franchise, they believe physicians still strongly prefer Stribild, Complera, Atripla, or any regimen containing a Truvada backbone.

Despite the approval, Oppenheimer's thesis on GILD remains unchanged with a $70 price target.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs